or Try an Advanced Search...

    Technical Analysis for ANTX - AN2 Therapeutics, Inc.

    Grade Last Price % Change Price Change
    D 1.08 0.00% 0.00
    ANTX closed unchanged on Friday, November 1, 2024, on 53 percent of normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions.
    0 Watchers
    Watchlist Portfolio

    Trend Table & Recent EOD Trading Signals

    ADX Long Term Intermediate Term Short Term
    Weak or Absent Down Up Flat
    Historical ANTX trend table...
    Date Alert Name Type % Chg
    Non-ADX 1,2,3,4 Bullish Bullish Swing Setup 0.00%
    NR7 Range Contraction 0.00%
    Narrow Range Bar Range Contraction 0.00%
    Inside Day Range Contraction 0.00%
    Gapped Up Strength 0.00%
    Upper Bollinger Band Walk Strength 0.00%
    Bearish Engulfing Bearish -0.92%
    Upper Bollinger Band Walk Strength -0.92%
    Upper Bollinger Band Touch Strength -0.92%
    Upper Bollinger Band Walk Strength -2.70%
    Older End-of-Day Signals for ANTX ...

       Recent Intraday Alerts

    Alert Time
    Possible NR7 about 19 hours ago
    Possible Inside Day about 19 hours ago
    10 DMA Resistance about 22 hours ago
    Up 1% about 22 hours ago
    Possible NR7 2 days ago
    View Earlier Intraday Alerts

    Get this analysis on your stocks daily!

    Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
    Track My Stocks
    Configure default chart indicators
    ANTX Chart by TradingView
    Basic chart:

    Profile

    AN2 Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing treatments for rare, chronic, and serious infectious diseases. It is developing epetraborole, a once-daily oral treatment for patients with chronic non-tuberculous mycobacterial lung disease. The company was incorporated in 2017 and is headquartered in Menlo Park, California.
    Classification
    Sector: Healthcare
    Industry: Biotechnology
    Keywords: Biopharmaceutical Infectious Diseases Microbiology Tuberculosis Bacteriology Nontuberculous Mycobacteria Serious Infectious Diseases

    Is ANTX a Buy, Sell or Hold?

    Indicator Bull Case Neutral / Hold Bear Case
    50 DMA
    200 DMA
    ADX Trend
    Oversold / Overbought
    Relative Strength
    Counts: 1 bullish, 2 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.

    Recent News

    Date Title
    Oct 3 Why Levi Strauss Shares Are Trading Lower By Over 10%; Here Are 20 Stocks Moving Premarket
    Aug 28 AN2 Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference
    Aug 19 AN2 Therapeutics (ANTX) Plunges 66% in a Month: Here's Why
    Aug 16 AN2 Therapeutics Adopts Limited Duration Stockholder Rights Plan
    Aug 14 AN2 Therapeutics GAAP EPS of -$0.48
    Aug 13 AN2 Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business and Scientific Highlights
    Aug 9 Top Midday Decliners
    Aug 9 US Stocks Edge Lower; EchoStar Shares Tumble After Q2 Results
    Aug 9 Lung Disease Focused AN2 Therapeutics' Lackluster Data Prompts To Stop Phase 3 Study Of Lung Infection Candidate, Halves Workforce
    Aug 9 AN2 slashes staff by 50% after lead antibiotic flunks in Phase II/III trial
    See more ANTX news...

    Comments

    View full discussion...

    Indicators

    Indicator Value
    52 Week High 22.15
    52 Week Low 0.87
    Average Volume 250,549
    200-Day Moving Average 3.54
    50-Day Moving Average 1.07
    20-Day Moving Average 1.06
    10-Day Moving Average 1.08
    Average True Range 0.04
    RSI (14) 48.72
    ADX 23.18
    +DI 21.66
    -DI 12.77
    Chandelier Exit (Long, 3 ATRs) 1.02
    Chandelier Exit (Short, 3 ATRs) 1.15
    Upper Bollinger Bands 1.11
    Lower Bollinger Band 1.02
    Percent B (%b) 0.68
    BandWidth 8.69
    MACD Line -0.01
    MACD Signal Line -0.01
    MACD Histogram 0.0095
    Fundamentals Value
    Market Cap 32.12 Million
    Num Shares 29.7 Million
    EPS -2.80
    Price-to-Earnings (P/E) Ratio -0.39
    Price-to-Sales 0.00
    Price-to-Book 4.28
    Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
    Resistance 4 (R4) 1.10
    Resistance 3 (R3) 1.10 1.10 1.09
    Resistance 2 (R2) 1.10 1.09 1.09 1.09
    Resistance 1 (R1) 1.09 1.09 1.09 1.09 1.09
    Pivot Point 1.08 1.08 1.08 1.08 1.08
    Support 1 (S1) 1.08 1.08 1.07 1.07 1.07
    Support 2 (S2) 1.07 1.08 1.07 1.07
    Support 3 (S3) 1.06 1.07 1.07
    Support 4 (S4) 1.06